 IV. To determine whether genomic polymorphisms of genes measured in peripheral blood mononuclear cells involved in the gemcitabine pathway RR and genes involved in the ras pathway VEGFR2, cyclin D, p21 will predict for time to progression, overall survival, tumor response, and toxicity in patients with advanced cancer of the pancreas treated with concurrent gemcitabine and BAY43-9006 and sequential BAY 43-9006 followed by gemcitabineBAY 43-9006 at progression. 